The influence of uveitis on patients with immune-mediated inflammatory disease

Journal of Rheumatology

Volumn 38, Issue SUPPL. 88, 2011, Pages 26-30

  Rosenbaum, James T ^a   Russell, Anthony S ^b   Guenther, Lyn C ^c   El Gabalawy, Hani ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Outcome assessment; Quality of life; Tumor necrosis factor ; Uveitis

Indexed keywords

ETANERCEPT; INFLIXIMAB; PLACEBO; ADALIMUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CAUSAL ATTRIBUTION; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA CYSTOID EDEMA; REVIEW; UVEITIS; VISUAL IMPAIRMENT; ANKYLOSING SPONDYLITIS; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VISUAL ACUITY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNE SYSTEM DISEASES; QUALITY OF LIFE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY;

EID: 84856018472     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110907     Document Type: Review

References (28)

1. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8. (Pubitemid 20350862)
2. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
3. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001;119:841-9. (Pubitemid 32530313)
4. Maini R, O'Sullivan J, Reddy A, Watson S, Edelsten C. The risk of complications of uveitis in a district hospital cohort. Br J Ophthalmol 2004;88:512-7. (Pubitemid 38437872)
5. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500. (Pubitemid 38293104)
6. Doesschate JT. Causes of blindness in the Netherlands. Doc Ophthalmol 1982;52:270-85.
7. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88:1159-62. (Pubitemid 39141376)
8. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6. (Pubitemid 26113585)
9. Janigian RH Jr. Uveitis evaluation and treatment. [Internet. Accessed August 2, 2011.] Available from: http://emedicine.medscape.com/article/1209123- overview
10. Monnet D, Breban M, Hudry C, Dougados M, Brézin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004;111:802-9. (Pubitemid 38429680)
11. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20 Suppl 28:S143-S145.
12. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9. (Pubitemid 351956657)
13. Kaçmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, et al Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008;146:828-36.
14. Verbraak FD, Schreinemachers MC, Tiller A, van Deventer SJ, de Smet MD. Prevalence of subclinical anterior uveitis in adult patients with inflammatory bowel disease. Br J Ophthalmol 2001;85:219-21. (Pubitemid 32146765)
15. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:135-9. (Pubitemid 38332174)
16. Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007;143:647-55.
17. Rabinovich CE, Wagner-Weiner L. Behcet syndrome. [Internet. Accessed August 2, 2011.] Available from: http://emedicine.medscape.com/article/1006358- overview
18. Murphy CC, Hughes EH, Frost NA, Dick AD. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol 2005;89:1161-5. (Pubitemid 41224468)
19. Mäntyjärvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. J Cataract Refract Surg 2001;27:261-6. (Pubitemid 32179506)
20. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 1998;116:1496-504. (Pubitemid 28520671)
21. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050-8. (Pubitemid 32652197)
22. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001;119:841-9. (Pubitemid 32530313)
23. Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behçet's disease. J Rheumatol 2004;31:931-7. (Pubitemid 38585817)
24. Haywood KL, Garratt AM, Jordan KP, Healey EL, Packham JC. Evaluation of ankylosing spondylitis quality of life (EASi-QoL): reliability and validity of a new patient-reported outcome measure. J Rheumatol 2010;37:2100-9.
25. Rosenbaum JT. Future for biological therapy for uveitis. Curr Opin Ophthalmol 2010;21:473-7.
26. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
27. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701.
28. Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50. (Pubitemid 46580481)